Below, we take a look at Madrigal (MDGL), a company that currently holds a Momentum Style Score of A. We also talk about price change and earnings estimate revisions, two of the main aspects of the ...

Madrigal stock catapulted again Friday after Novo Nordisk published not "game-changing" results for its MASH treatment.

In its second full quarter on the market, the fatty liver disease drug racked up sales of $62 million, which routed Wall ...

Madrigal Pharmaceuticals MDGL reported third-quarter 2024 loss of $4.92 per share, narrower than the Zacks Consensus Estimate ...

With the FDA approval of the first specific drug for Metabolic Associated Steatohepatitis (MASH) in March this year, Madrigal’s Rezdiffra is a pioneer in a market set for rapid change. | With the FDA ...

B. Riley analyst Mayank Mamtani raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $236 from $194 and keeps a Neutral rating on the shares. Madrigal’s Q3 earnings “blowout” print ...

CONSHOHOCKEN, Pa., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in fireside chats at three upcoming investor ...

Madrigal Pharmaceuticals Inc (MDGL) reports robust Q3 sales driven by Rezdiffra demand, while navigating increased SG&A ...

Madrigal Pharmaceuticals' Rezdiffra has favorable initial market adoption and FDA approval. Read why I maintain my buy rating ...

Chief Executive Officer of Madrigal, Bill Sibold, highlighted the successful launch of Rezdiffra™ (resmetirom) in the U.S., emphasizing strong adoption by prescribers and increasing patient ...

Regeneron shares continued to decline on growing concerns about Eylea’s future. Elsewhere, new details emerged about Lundbeck ...